ANIZOME LLC, a company dedicated to the commercial application of microbiome science in animal health by leveraging insights from the role of the microbiome in human healthcare, has announced the appointment of Dr. Bénédicte Flambard as the Chairperson of its Board of Directors.
Dr. Flambard specialises in heading the innovation and development of commercial strategies within the animal and human healthcare sectors. She is currently Global Head of Plant Health Business at chemical manufacturing company FMC Corporation.
Dr. Flambard has previously served as a Global Head of Live BioTherapeutics & Nutraceuticals at Boehringer Ingelheim, where she led the creation of a new business unit, combining novel microbial based bio-therapeutic and diagnostic approaches. She has also worked for Merial and Chr. Hansen, the world leader in microbial solutions. Dr. Flambard holds several vice president positions in the health and agriculture industries, as well as trustee positions and advisory roles for organisations in the consumer goods, pharmaceuticals and technology sectors. While growing core businesses, she has experience of seeding and developing growth opportunities into start-up businesses, focusing exclusively on the microbiome.
Dr. Flambard has a Master of Administration from the University of Bath in the UK, a PhD in Molecular Genetics and Microbial Physiology from the National Institute of Agronomic in France, and a Master in Corporate Entrepreneurial Leadership from the Centre for Technology Economics & Management in Denmark.
ANIZOME’s board of directors now consists of Dr. Bénédicte Flambard, Chairperson; Matthias Hofer, Founder and Non-Executive Director at Stonehaven Incubate AG; Shawn Davis VP & Chief Ventures Officer, Baylor College of Medicine; Joseph Petrosino PhD, ANIZOME’s CSO and the Chairman of the Department of Molecular Virology and Microbiology and Head of the Center for Metagenomics and Microbiome Research at Baylor College of Medicine; and Caroline Popper MD MPH, ANIZOME’s CEO.